相关实验视频

Updated: Sep 20, 2025

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

协生补充剂通过提高肠道微生物群组成和肠道屏障功能来缓解与抗生素相关的腹,在狗模型中

Haoyi Shen¹, Yiran Zhao¹, Sizhe Zhang¹

¹Animal Science and Technology College, Beijing University of Agriculture, Beijing, 102206, People's Republic of China.

Probiotics and antimicrobial proteins

|May 27, 2025

概括

协生菌是一种有益细菌和益生菌的混合物,有效治疗狗的抗生素相关腹 (AAD). 这种治疗通过改善肠道屏障功能和减少炎症来恢复肠道健康.

科学领域:

兽医医学兽医医学兽医医学
微生物学微生物学
胃肠病学胃肠病学

背景情况:

与抗生素相关的腹 (AAD) 是一个重大的临床挑战.
目前对AAD的治疗方法往往无法完全恢复肠道健康.
协生菌为AAD提供了潜在的治疗途径.

研究的目的:

评估协生菌在犬模型中减轻AAD的疗效.
评估协生菌对肠道微生物群,肠道形态和屏障功能的影响.
为了研究ADD中协生菌的抗炎作用.

主要方法:

用了16只比格尔犬,随机分配到AAD模型或共生治疗组.
协生菌的配方包括奇托寡糖,Bifidobacterium,Clostridium butyricum和Lactiplantibacillus plantarum等.
分析了肠道形态,肠道微生物群的多样性,紧结蛋白表达,粘膜透性和细胞因子水平.

主要成果:

同生菌补充剂显著降低了腹的严重程度,改善了肠道形态.
在共生治疗后,肠道微生物群的多样性得到了增强.
协生菌上调紧结蛋白 (ZO-1,ocludin,claudin-1),降低了粘膜的透性,并降低了促炎细胞因子 (IL-1β,TNF-α).

结论:

协生菌在恢复肠道屏障完整性和调节AAD中的免疫反应方面表现有前途.
这项研究强调了协生菌作为AAD治疗策略的潜力.
需要进一步的研究来探索共生菌在肠道健康恢复中的长期影响和机制.

关键词:

与抗生素相关的腹.基托的寡糖化物.肠道菌群是什么意思肠道菌群益生菌益生菌益生菌综合生菌综合生菌

更多相关视频

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach

Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach

Published on: May 2, 2018

相关概念视频

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...